 The researchers discovered that a new gene, TCHAP-10, is a target of the AML1-ETO fusion protein and is epigenetically suppressed by the AML1-ETO fusion protein. They also found that this gene is regulated by microRNA-383, which is controlled by the AML1-ETO fusion protein. The researchers then showed that TCHAP-10 is a nuclear protein that inhibits myeloid proliferation and promotes differentiation both in vitro and in vivo. Finally, they concluded that the epigenetic suppression of TCHAP-10 predicts a poor clinical outcome and represents a novel therapeutic target for T8-21, acute myeloid leukemia. This article was authored by Yonghui Li, Chaoyang Ning, Jim Longsha, and others.